Aspirin May Prevent Heart Complications in Pneumonia Patients: ECCMID Study
A study presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) suggests that aspirin could play a future role in preventing cardiovascular complications in pneumonia patients. Led by Dr Fergus Hamilton from the University of Bristol, UK, the research found that aspirin users had a 36% lower risk of stroke and myocardial infarction (MI) compared to non-users.
The study, which analyzed data from the large UK primary care database Clinical Practice Research Datalink (CPRD), compared 8099 aspirin users with 8099 non-users. The primary outcome was the occurrence of both ischemic stroke and MI, while either event individually was a secondary outcome. Aspirin use was associated with a reduced risk of both secondary outcomes, with ischemic stroke and MI rates being 30% and 54% lower, respectively, in aspirin users. Dr Hamilton, currently involved in a project on postconflict reconstruction in Sierra Leone, noted that aspirin's antiplatelet effect might explain its protective role in pneumonia patients.
The study, published in the Journal of Clinical Microbiology, highlights aspirin's potential in preventing cardiovascular complications in pneumonia patients. Further research is needed to confirm these findings and determine the optimal dosage and duration of aspirin therapy for this purpose.
Read also:
- Abu Dhabi initiative for comprehensive genetic screening, aiming to diagnose over 800 conditions and enhance the health of future generations in the UAE.
- Elderly shingles: Recognizing symptoms, potential problems, and available treatments
- Exploring the Reasons, Purposes, and Enigmas of Hiccups: Delving into Their Origins, Roles, and Unsolved Aspects
- Various forms of cataracts include nuclear, pediatric, traumatic, and additional types
